B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells
Open Access
- 30 April 2012
- journal article
- research article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 209 (5), 1001-1010
- https://doi.org/10.1084/jem.20111675
Abstract
B cells have paradoxical roles in autoimmunity, exerting both pathogenic and protective effects. Pathogenesis may be antibody independent, as B cell depletion therapy (BCDT) leads to amelioration of disease irrespective of autoantibody ablation. However, the mechanisms of pathogenesis are poorly understood. We demonstrate that BCDT alleviates central nervous system autoimmunity through ablation of IL-6–secreting pathogenic B cells. B cells from mice with experimental autoimmune encephalomyelitis (EAE) secreted elevated levels of IL-6 compared with B cells from naive controls, and mice with a B cell–specific IL-6 deficiency showed less severe disease than mice with wild-type B cells. Moreover, BCDT ameliorated EAE only in mice with IL-6–sufficient B cells. This mechanism of pathogenesis may also operate in multiple sclerosis (MS) because B cells from MS patients produced more IL-6 than B cells from healthy controls, and this abnormality was normalized with B cell reconstitution after Rituximab treatment. This suggests that BCDT improved disease progression, at least partly, by eliminating IL-6–producing B cells in MS patients. Taking these data together, we conclude that IL-6 secretion is a major mechanism of B cell–driven pathogenesis in T cell–mediated autoimmune disease such as EAE and MS.Keywords
This publication has 50 references indexed in Scilit:
- IL-17 receptor signaling and T helper 17-mediated autoimmune demyelinating diseaseTrends in Immunology, 2011
- Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluidAnnals of Neurology, 2009
- IL-6 blockade inhibits the induction of myelin antigen-specific Th17 cells and Th1 cells in experimental autoimmune encephalomyelitisProceedings of the National Academy of Sciences of the United States of America, 2008
- IL-12– and IL-23–modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibitionThe Journal of Experimental Medicine, 2008
- A Regulatory B Cell Subset with a Unique CD1dhiCD5+ Phenotype Controls T Cell-Dependent Inflammatory ResponsesImmunity, 2008
- TLR‐mediated stimulation of APC: Distinct cytokine responses of B cells and dendritic cellsEuropean Journal of Immunology, 2007
- Identification of a pathogenic antibody response to native myelin oligodendrocyte glycoprotein in multiple sclerosisProceedings of the National Academy of Sciences of the United States of America, 2006
- Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patientsJournal of Neuroimmunology, 2006
- Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature, 2006
- Blood Dendritic Cells Interact with Splenic Marginal Zone B Cells to Initiate T-Independent Immune ResponsesImmunity, 2002